Compare Stocks: OCS, OCUL, TRLV, and PBH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCS Oculis	$9.98 +0.7%	$12.10	$9.65 ▼ $34.47	$574.63M	0.52	151,768 shs	248,044 shs
OCUL Ocular Therapeutix	$10.14 +2.7%	$9.88	$6.23 ▼ $16.44	$2.17B	0.97	2.06 million shs	2.31 million shs
PBH Prestige Consumer Healthcare	$46.52 -0.7%	$50.64	$42.62 ▼ $71.07	$2.22B	0.33	436,303 shs	504,031 shs
TRLV Trulieve Cannabis	$11.68 +1.1%	$9.99	$4.62 ▼ $13.28	$2.22B	N/A	1.55 million shs	1.57 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCS Oculis	+0.71%	-11.76%	-24.34%	-11.05%	-42.64%
OCUL Ocular Therapeutix	+2.74%	-4.52%	-7.90%	+7.53%	-16.61%
PBH Prestige Consumer Healthcare	-0.81%	-1.85%	-8.18%	-1.01%	-27.16%
TRLV Trulieve Cannabis	+0.93%	+2.98%	+20.65%	+18.10%	+1,167,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OCS Oculis	$9.98 +0.7%	$12.10	$9.65 ▼ $34.47	$574.63M	0.52	151,768 shs	248,044 shs
OCUL Ocular Therapeutix	$10.14 +2.7%	$9.88	$6.23 ▼ $16.44	$2.17B	0.97	2.06 million shs	2.31 million shs
PBH Prestige Consumer Healthcare	$46.52 -0.7%	$50.64	$42.62 ▼ $71.07	$2.22B	0.33	436,303 shs	504,031 shs
TRLV Trulieve Cannabis	$11.68 +1.1%	$9.99	$4.62 ▼ $13.28	$2.22B	N/A	1.55 million shs	1.57 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OCS Oculis	+0.71%	-11.76%	-24.34%	-11.05%	-42.64%
OCUL Ocular Therapeutix	+2.74%	-4.52%	-7.90%	+7.53%	-16.61%
PBH Prestige Consumer Healthcare	-0.81%	-1.85%	-8.18%	-1.01%	-27.16%
TRLV Trulieve Cannabis	+0.93%	+2.98%	+20.65%	+18.10%	+1,167,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OCS Oculis	2.80	Moderate Buy	$38.00	280.76% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	153.94% Upside
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	52.10% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	28.42% Upside

Current Analyst Ratings Breakdown

Latest OCS, OCUL, TRLV, and PBH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/11/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	OCS Oculis	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$23.00 ➝ $20.00
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/7/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$15.00
8/5/2026	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/4/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/20/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$15.00

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OCS Oculis	$1.45M	399.06	N/A	N/A	$4.08 per share	2.45
OCUL Ocular Therapeutix	$51.95M	42.87	N/A	N/A	$3.07 per share	3.30
PBH Prestige Consumer Healthcare	$1.09B	2.02	$5.17 per share	9.00	$39.89 per share	1.17
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OCS Oculis	-$119.44M	-$1.74	N/A	N/A	N/A	-6,777.18%	-42.61%	-35.23%	11/5/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.03	9.14	1.47	15.57%	11.39%	5.66%	11/5/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	20.49	N/A	N/A	N/A	N/A	N/A

Latest OCS, OCUL, TRLV, and PBH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2026	Q2 2026	TRLV Trulieve Cannabis	$0.06	$0.11	+$0.05	-$2.10	$268.82 million	$271.00 million
8/6/2026	Q2 2026	OCS Oculis	-$0.48	-$0.20	+$0.28	-$0.20	$0.22 million	$0.38 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
6/30/2026	Q2 2026	OCS Oculis	N/A	-$0.20	N/A	-$0.20	N/A	$0.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
OCS Oculis	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OCS Oculis	0.01	8.35	8.35
OCUL Ocular Therapeutix	0.14	13.10	13.03
PBH Prestige Consumer Healthcare	1.06	3.23	1.99
TRLV Trulieve Cannabis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OCS Oculis	22.30%
OCUL Ocular Therapeutix	59.21%
PBH Prestige Consumer Healthcare	99.95%
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
OCS Oculis	N/A
OCUL Ocular Therapeutix	3.10%
PBH Prestige Consumer Healthcare	1.50%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OCS Oculis	60	57.98 million	N/A	Not Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
PBH Prestige Consumer Healthcare	890	47.38 million	46.66 million	Optionable
TRLV Trulieve Cannabis	5,000	192.57 million	185.27 million	N/A

OCS, OCUL, TRLV, and PBH Headlines

Recent News About These Companies

Best Cannabis Stocks Worth Watching - September 15th

1 hour ago | americanbankingnews.com

Cannabis Stocks To Follow Today - September 13th

September 16 at 3:34 AM | americanbankingnews.com

Cannabis Stocks To Consider - September 12th

September 15 at 3:03 AM | americanbankingnews.com

Curaleaf: Favorable Court Ruling Doesn't Repay Debt

September 14, 2026 | seekingalpha.com

Best Cannabis Stocks To Watch Now - September 10th

September 13, 2026 | americanbankingnews.com

Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards

September 11, 2026 | seekingalpha.com

Top Cannabis Stocks Worth Watching - September 11th

September 11, 2026 | marketbeat.com

Cannabis Stocks To Watch Today - September 8th

September 9, 2026 | americanbankingnews.com

Trulieve Cannabis Corp ouvre un dispensaire de cannabis médical à Dunwoody, en Géorgie

September 5, 2026 | zonebourse.comZ

Trulieve Expands Georgia Presence With New Dunwoody Medical Cannabis Dispensary

September 4, 2026 | tipranks.com

Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia

September 4, 2026 | prnewswire.com

Trulieve Announces September 2026 Event Participation

September 2, 2026 | prnewswire.com

Trulieve Cannabis (NYSE:TRLV) Trading Up 4.7% - What's Next?

September 1, 2026 | marketbeat.com

3 Marijuana Stocks To Focus On For Future Growth And Profits

August 31, 2026 | marijuanastocks.comM

Cannabis Stocks To Watch Now - August 29th

August 29, 2026 | marketbeat.com

Cannabis Stocks To Follow Now - August 26th

August 26, 2026 | marketbeat.com

Trulieve Cannabis (NYSE:TRLV) Stock Price Up 4.5% - Here's Why

August 26, 2026 | marketbeat.com

Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE

August 18, 2026 | prnewswire.com

3 Marijuana Stocks For Investors To Consider

August 12, 2026 | marijuanastocks.comM

Trulieve Completes Redomicile from British Columbia to Delaware

August 11, 2026 | prnewswire.com

Trulieve Cannabis (TRLV) Reports Steeper Losses And Lower Sales, Is The Valuation Discount Justified?

August 8, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, OCUL, TRLV, and PBH Company Descriptions

Oculis NASDAQ:OCS

$9.98 +0.07 (+0.71%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$9.97 -0.01 (-0.06%)

As of 04:00 AM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Ocular Therapeutix NASDAQ:OCUL

$10.14 +0.27 (+2.74%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$10.18 +0.04 (+0.36%)

As of 04:01 AM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$46.52 -0.34 (-0.73%)

Closing price 09/17/2026 03:59 PM Eastern

Extended Trading

$46.48 -0.04 (-0.08%)

As of 09/17/2026 07:30 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Trulieve Cannabis NYSE:TRLV

$11.68 +0.13 (+1.13%)

Closing price 09/17/2026 03:59 PM Eastern

Extended Trading

$11.74 +0.05 (+0.47%)

As of 04:26 AM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCS, OCUL, TRLV, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCS, OCUL, TRLV, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCS, OCUL, TRLV, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, OCUL, TRLV, and PBH Company Descriptions

Oculis NASDAQ:OCS

Ocular Therapeutix NASDAQ:OCUL

Prestige Consumer Healthcare NYSE:PBH

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCS, OCUL, TRLV, and PBH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCS, OCUL, TRLV, and PBH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCS, OCUL, TRLV, and PBH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS, OCUL, TRLV, and PBH Company Descriptions

Oculis NASDAQ:OCS

Ocular Therapeutix NASDAQ:OCUL

Prestige Consumer Healthcare NYSE:PBH

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools